158 related articles for article (PubMed ID: 20505749)
1. Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: the LIFE study.
Larstorp AC; Okin PM; Devereux RB; Olsen MH; Ibsen H; Dahlöf B; Kjeldsen SE; Wachtell K
J Hum Hypertens; 2011 Mar; 25(3):178-85. PubMed ID: 20505749
[TBL] [Abstract][Full Text] [Related]
2. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Nieminen MS; Snapinn S; Harris KE; Aurup P; Edelman JM; Dahlof B;
Circulation; 2003 Aug; 108(6):684-90. PubMed ID: 12885747
[TBL] [Abstract][Full Text] [Related]
3. Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators.
Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Dahlöf B
Hypertension; 2000 Nov; 36(5):766-73. PubMed ID: 11082141
[TBL] [Abstract][Full Text] [Related]
4. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study].
Ibsen H; Pedersen OL; Dahlöf B; Kjeldsen SE; Lindholm LH
Ugeskr Laeger; 2003 Jan; 165(5):456-9. PubMed ID: 12599843
[TBL] [Abstract][Full Text] [Related]
5. Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Dahlöf B; Burke TA; Krobot K; Carides GW; Edelman JM; Devereux RB; Diener HC
J Hum Hypertens; 2004 Jun; 18(6):367-73. PubMed ID: 15029217
[TBL] [Abstract][Full Text] [Related]
6. Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients : the losartan intervention for endpoint (LIFE) reduction in hypertension study.
Okin PM; Jern S; Devereux RB; Kjeldsen SE; Dahlöf B;
Hypertension; 2000 Jan; 35(1 Pt 1):13-8. PubMed ID: 10642268
[TBL] [Abstract][Full Text] [Related]
7. Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study.
Oikarinen L; Nieminen MS; Toivonen L; Viitasalo M; Wachtell K; Papademetriou V; Jern S; Dahlöf B; Devereux RB; Okin PM;
Am Heart J; 2003 May; 145(5):919-25. PubMed ID: 12766755
[TBL] [Abstract][Full Text] [Related]
8. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Kjeldsen SE; Dahlöf B; Devereux RB; Julius S; Aurup P; Edelman J; Beevers G; de Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Snapinn S; Wedel H;
JAMA; 2002 Sep; 288(12):1491-8. PubMed ID: 12243636
[TBL] [Abstract][Full Text] [Related]
9. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
Dahlöf B; Devereux R; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Julius S; Kjeldsen S; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
Am J Hypertens; 1997 Jul; 10(7 Pt 1):705-13. PubMed ID: 9234823
[TBL] [Abstract][Full Text] [Related]
10. Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study.
Devereux RB; Palmieri V; Liu JE; Wachtell K; Bella JN; Boman K; Gerdts E; Nieminen MS; Papademetriou V; Dahlöf B
J Hypertens; 2002 Jul; 20(7):1445-50. PubMed ID: 12131543
[TBL] [Abstract][Full Text] [Related]
11. Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Wachtell K; Dahlöf B; Rokkedal J; Papademetriou V; Nieminen MS; Smith G; Gerdts E; Boman K; Bella JN; Devereux RB
Am Heart J; 2002 Dec; 144(6):1057-64. PubMed ID: 12486431
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension.
Dahlöf B; Devereux RB; Julius S; Kjeldsen SE; Beevers G; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
Hypertension; 1998 Dec; 32(6):989-97. PubMed ID: 9856962
[TBL] [Abstract][Full Text] [Related]
13. Relation of echocardiographic left ventricular mass and hypertrophy to persistent electrocardiographic left ventricular hypertrophy in hypertensive patients: the LIFE Study.
Okin PM; Devereux RB; Jern S; Julius S; Kjeldsen SE; Dahlöf B
Am J Hypertens; 2001 Aug; 14(8 Pt 1):775-82. PubMed ID: 11497193
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of a new electrocardiographic method for diagnosis of left ventricular hypertrophy in essential hypertension.
Verdecchia P; Schillaci G; Borgioni C; Ciucci A; Gattobigio R; Zampi I; Porcellati C
J Am Coll Cardiol; 1998 Feb; 31(2):383-90. PubMed ID: 9462583
[TBL] [Abstract][Full Text] [Related]
15. Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study.
Wachtell K; Bella JN; Rokkedal J; Palmieri V; Papademetriou V; Dahlöf B; Aalto T; Gerdts E; Devereux RB
Circulation; 2002 Mar; 105(9):1071-6. PubMed ID: 11877357
[TBL] [Abstract][Full Text] [Related]
16. Electrocardiographic criteria which have the best prognostic significance in hypertensive patients with echocardiographic hypertrophy of left ventricle: 15-year prospective study.
Djordjevic DB; Tasic IS; Kostic ST; Stamenkovic BN; Lovic MB; Djordjevic ND; Koracevic GP; Lovic DB
Clin Cardiol; 2020 Sep; 43(9):1017-1023. PubMed ID: 32492247
[TBL] [Abstract][Full Text] [Related]
17. Ethnic differences in electrocardiographic criteria for left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint.
Okin PM; Wright JT; Nieminen MS; Jern S; Taylor AL; Phillips R; Papademetriou V; Clark LT; Ofili EO; Randall OS; Oikarinen L; Viitasalo M; Toivonen L; Julius S; Dahlöf B; Devereux RB
Am J Hypertens; 2002 Aug; 15(8):663-71. PubMed ID: 12160187
[TBL] [Abstract][Full Text] [Related]
18. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study.
Wachtell K; Olsen MH; Dahlöf B; Devereux RB; Kjeldsen SE; Nieminen MS; Okin PM; Papademetriou V; Mogensen CE; Borch-Johnsen K; Ibsen H
J Hypertens; 2002 Mar; 20(3):405-12. PubMed ID: 11875307
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Dahlöf B; Devereux RB; Kjeldsen SE; Julius S; Beevers G; de Faire U; Fyhrquist F; Ibsen H; Kristiansson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H;
Lancet; 2002 Mar; 359(9311):995-1003. PubMed ID: 11937178
[TBL] [Abstract][Full Text] [Related]
20. Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial.
Devereux RB; Dahlöf B; Kjeldsen SE; Julius S; Aurup P; Beevers G; Edelman JM; de Faire U; Fyhrquist F; Helle Berg S; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Snapinn S; Wedel H;
Ann Intern Med; 2003 Aug; 139(3):169-77. PubMed ID: 12899584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
